Natalia Jiménez
Grup de recerca
- Genòmica translacional i teràpies dirigides en tumors sòlids Assistant researcher (R2C)
Publicacions destacades
-
Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes
Autors:Referència: Cancers 2021. -
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Autors:Referència: Frontiers In Oncology 2020. -
Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
Autors:Referència: Cells 2020. -
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
Autors:Referència: International Journal Of Cancer 2019. -
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
Autors:Referència: European Urology 2016. -
Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients
Autors:Referència: Clinical Genitourinary Cancer 2016. -
Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
Autors:Referència: Oncotarget 2015. -
Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Autors:Referència: Molecular Cancer Therapeutics 2014.
Projectes destacats
-
Plasticidad celular y perfil inmune asociados al tratamiento en cáncer de próstata metastásico
Finançador: Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) (Sede o evento); Instituto de Salud Carlos IIIDurada: 01/01/2019 - 31/12/2021 -
Caracterización molecular del cáncer de próstata en función de la expresión de TMPRSS2-ERG: implicaciones terapéuticas
Finançador: Institut D'investigacions Biomediques August Pi i Sunyer (Idibaps) (Sede o evento); Instituto de Salud Carlos IIIDurada: 01/01/2016 - 31/12/2018